39 related articles for article (PubMed ID: 32447503)
1. [A retrospective analysis of 6 children with Duchenne muscular dystrophy].
Yin YJ; Huang YP; Lu C; Sun XP; Niu FN; Jin R; Zhou GP
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Apr; 19(4):405-409. PubMed ID: 28407826
[TBL] [Abstract][Full Text] [Related]
2. Histopathologic Changes of the Esophagus in Duchenne Muscular Dystrophy.
Marshall MR; Reyes-Múgica M
Int J Surg Pathol; 2024 Feb; 32(1):17-20. PubMed ID: 37063046
[TBL] [Abstract][Full Text] [Related]
3. Duchenne Muscular Dystrophy Newborn Screening: Evaluation of a New GSP
Timonen A; Lloyd-Puryear M; Hougaard DM; Meriö L; Mäkinen P; Laitala V; Pölönen T; Skogstrand K; Kennedy A; Airenne S; Polari H; Korpimäki T
Int J Neonatal Screen; 2019 Sep; 5(3):27. PubMed ID: 33072986
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.
Boca SM; Nishida M; Harris M; Rao S; Cheema AK; Gill K; Seol H; Morgenroth LP; Henricson E; McDonald C; Mah JK; Clemens PR; Hoffman EP; Hathout Y; Madhavan S
PLoS One; 2016; 11(4):e0153461. PubMed ID: 27082433
[TBL] [Abstract][Full Text] [Related]
5. A case of Duchenne muscular dystrophy recovered from prolonged ischemic kidney injury which emerged with a normal creatinine level.
Daikoku K; Kondo H; Kudo M; Sugiura A
CEN Case Rep; 2024 Mar; ():. PubMed ID: 38436872
[TBL] [Abstract][Full Text] [Related]
6. Age-Related Blood Levels of Creatine Kinase-MM in Newborns and Patients with Duchenne Muscular Dystrophy: Considerations for the Development of Newborn Screening Algorithms.
Potter SN; Migliore B; Carter J; Copeland VR; Smith EC; Peay HL; Kucera KS
Int J Neonatal Screen; 2024 Jun; 10(2):. PubMed ID: 38920848
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in nephrology: Core Curriculum 2013.
McMahon GM; Waikar SS
Am J Kidney Dis; 2013 Jul; 62(1):165-78. PubMed ID: 23455173
[No Abstract] [Full Text] [Related]
8. A new imaging sign in COVID-19 pneumonia: vascular changes and their correlation with clinical severity of the disease.
Tekcan Şanlı DE; Yıldırım D
Diagn Interv Radiol; 2021 Mar; 27(2):172-180. PubMed ID: 33044171
[TBL] [Abstract][Full Text] [Related]
9. The CELIOtomy Risk Score: An effort to minimize futile surgery with analysis of early postoperative mortality after emergency laparotomy.
Kao AM; Maloney SR; Prasad T; Reinke CE; May AK; Heniford BT; Ross SW
Surgery; 2020 Oct; 168(4):676-683. PubMed ID: 32703678
[TBL] [Abstract][Full Text] [Related]
10. Systemic Inflammatory Markers Predict Detrimental Outcome of Urosepsis in Kidney Transplant Recipients.
Królicki T; Bardowska K; Kościelska-Kasprzak K; Mazanowska O; Krajewska M; Kamińska D
Transplant Proc; 2020 Oct; 52(8):2382-2387. PubMed ID: 32571705
[TBL] [Abstract][Full Text] [Related]
11. RENAL, HEPATIC AND IMMUNE FUNCTION INDICES IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY.
Kononets O; Karaiev T; Tkachenko O; Lichman L
Georgian Med News; 2020 Dec; (309):64-71. PubMed ID: 33526732
[TBL] [Abstract][Full Text] [Related]
12. How Can Proteomics Help to Elucidate the Pathophysiological Crosstalk in Muscular Dystrophy and Associated Multi-System Dysfunction?
Dowling P; Trollet C; Negroni E; Swandulla D; Ohlendieck K
Proteomes; 2024 Jan; 12(1):. PubMed ID: 38250815
[TBL] [Abstract][Full Text] [Related]
13. The Importance of Implementing a Transition Strategy for Patients with Muscular Dystrophy: From Child to Adult-Insights from a Tertiary Centre for Rare Neurological Diseases.
Lupu M; Ioghen M; Perjoc RȘ; Scarlat AM; Vladâcenco OA; Roza E; Epure DA; Teleanu RI; Severin EM
Children (Basel); 2023 May; 10(6):. PubMed ID: 37371191
[TBL] [Abstract][Full Text] [Related]
14. Histological and Histochemical Microscopy Used to Verify 2D-DIGE Pathoproteomics.
Zweyer M; Ohlendieck K; Swandulla D
Methods Mol Biol; 2023; 2596():465-480. PubMed ID: 36378457
[TBL] [Abstract][Full Text] [Related]
15. Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy.
Ohlendieck K; Swandulla D
Pflugers Arch; 2021 Dec; 473(12):1813-1839. PubMed ID: 34553265
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Bladder and Bowel Dysfunction in Duchenne Muscular Dystrophy Using the Childhood Bladder and Bowel Dysfunction Questionnaire.
Lionarons JM; de Groot IJM; Fock JM; Klinkenberg S; Vrijens DMJ; Vreugdenhil ACE; Medici-van den Herik EG; Cuppen I; Jaeger B; Niks EH; Hoogerhuis R; Platte-van Attekum N; Feron FJM; Faber CG; Hendriksen JGM; Vles JSH
Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440515
[TBL] [Abstract][Full Text] [Related]
17. Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial.
McDonald CM; Shieh PB; Abdel-Hamid HZ; Connolly AM; Ciafaloni E; Wagner KR; Goemans N; Mercuri E; Khan N; Koenig E; Malhotra J; Zhang W; Han B; Mendell JR;
J Neuromuscul Dis; 2021; 8(6):989-1001. PubMed ID: 34120909
[TBL] [Abstract][Full Text] [Related]
18. Kidney involvement and associated risk factors in children with Duchenne muscular dystrophy.
Kutluk MG; Doğan ÇS
Pediatr Nephrol; 2020 Oct; 35(10):1953-1958. PubMed ID: 32447503
[TBL] [Abstract][Full Text] [Related]
19. Treatable renal failure found in non-ambulatory Duchenne muscular dystrophy patients.
Motoki T; Shimizu-Motohashi Y; Komaki H; Mori-Yoshimura M; Oya Y; Takeshita E; Ishiyama A; Saito T; Nakagawa E; Sugai K; Murata M; Sasaki M
Neuromuscul Disord; 2015 Oct; 25(10):754-7. PubMed ID: 26298609
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
